Vaccination with Tumor Lysate-Pulsed Dendritic Cells Elicits Antigen-Specific, Cytotoxic T-Cells in Patients with Malignant Glioma

John S. Yu,1 Gentao Liu,1 Han Ying,1 William H. Yong,2 Keith L. Black,1 and Christopher J. Wheeler1

1Maxine Dunitz Neurosurgical Institute and 2Department of Pathology, Cedars-Sinai Medical Center, Los Angeles, California

INTRODUCTION

Glioblastoma multiforme (GBM) is the most aggressive and common primary brain tumor, accounting for 50% of intracranial gliomas and 25% of intracranial tumors in adults (1). GBM diagnosis carries with it a median survival of 12–18 months (with 90–95% of patients surviving <2 years), without the possibility of spontaneous remission (2). Current treatment, consisting of surgical resection followed by radiation therapy and chemotherapy, has not substantially changed the treatment for patients with non-glioma tumors (3, 4). Even the few treatments that have been found to be effective against GBM typically either exhibit only small increases in survival in large population studies or primarily benefit certain patient subpopulations, such as the young (5, 6). The overwhelming majority of patients with malignant glioma, composed of GBM and anaplastic astrocytoma (AA), experience increasingly rapid tumor recurrence after surgical resection or other treatment and eventually succumb to such events. Thus, novel therapies for malignant gliomas and recurrent gliomas, in particular, are desperately needed.

Cancer vaccines represent one novel form of therapy for recurrent malignant glioma (7). The clinical efficacy of therapeutic vaccination for any human tumor, however, remains controversial because consistent tumor destruction or extended life span is not observed in most vaccinated cancer patients (8–11). In contrast, current cancer vaccines do reliably elicit tumor-reactive CTLs in most patients (8–11). Consistent with this finding, we reported previously that therapeutic vaccination with autologous tumor peptide-pulsed dendritic cells (DCs) is sufficient to enhance peripheral tumor-reactive CTL activity and CD8+ T-cell infiltration into tumors in situ in newly diagnosed GBM patients (12).

In the above-mentioned study, vaccine generation was constrained by the time required to obtain peptide antigen from each patient’s autologous cultured tumor cell line. The generation of such lines is particularly difficult in recurrent patients, whose tumors have been exposed to radiation. We therefore examined the ability of tumor lysate-pulsed DCs to activate peripheral tumor-reactive CTL activity and CD8+ T-cell infiltration into tumors in situ in recurrent malignant glioma patients.

Here, we use autologous tumor lysate-pulsed DCs to introduce undefined tumor-associated antigens (TAA) to the T cells of patients with recurrent as well as newly diagnosed malignant glioma. These biweekly intradermal lysate-pulsed DC vaccinations were administered to nine patients with recurrent GBM and three patients with recurrent AA. One patient with newly diagnosed GBM and one patient with newly diagnosed AA were also treated. A potential risk of vaccine therapy, particularly for tumors within essential organs such as the brain, is destructive autoimmunity. Traditionally, the concern over autoimmunity has been addressed by targeting vaccines to specific antigenic epitopes not present on vital host tissues. Vaccines using undefined mixtures of tumor antigens have been reported to support sustained antitumor responses more effectively than peptide-based vaccines. A balance, however, must be struck between specificity and the ability of the tumor to evade responses directed toward a limited set of antigens. In addition, as vaccines for brain tumors become increasingly effective for treating patients, it will be necessary to move from approaches at higher risk for destructive autoimmunity toward those specifically targeting tumor tissue. One such method would be to use glioma-associated antigens. We sought to characterize common tumor antigen epitopes to which malignant glioma patients responded after vaccination with undefined autologous tumor antigen. We recently demonstrated the expression of TAA in glioblastoma and demonstrated the presentation of some common TAA epitopes in a MHC-restricted fashion (13, 14). We used these findings to determine whether DC vaccination generated T-cell clones that recognized these epitopes.

No significant adverse effects were associated with DC vaccination. One patient was tested for tumor-specific T-cell cytotoxicity through a conventional CTL assay and demonstrated robust cytotoxicity after vaccination. Ten additional patients had pre- and postvaccination CTL assays based on quantitative reverse transcription-PCR detection of IFN-γ expression. Six patients demonstrated significant peripheral cytotoxicity postvaccination based on IFN-γ expression. A subset of patients demonstrated the generation of not only tumor-specific T cells but also tumor antigen-specific T cells after DC vaccination. Six patients underwent reoperation for recurrence, and three of these patients demonstrated significant CD4+ and CD8+ tumor infiltration. We also compared survival rates for the eight study patients with recurrent GBM with those of 26 control patients with recurrent GBM.
who underwent craniotomy at our institution around the same time period. Tumor lysate-pulsed DC vaccination was associated with a 133-week median survival as compared with a 30-week median survival for 26 control patients. This Phase I study demonstrates the feasibility and safety of an autologous peptide-pulsed DC vaccine for malignant glioma.

MATERIALS AND METHODS

Patient Population. Inclusion criteria were a Karnofsky score of ≥60, an age of ≥18 years, lowest possible maintenance dose of glucocorticoid therapy, and the following normal baseline hematological parameters (within 1 week before first vaccination): hemoglobin >9.9 g/dl; total granulocyte count >1,000/ml; platelet count >60,000/ml; BUN <30 mg/dl; creatinine <2 mg/dl; alkaline phosphatase, alanine aminotransferase, and aspartate aminotransferase <2× the upper limit of normal; and a prothrombin time and activated partial thromboplastin time no greater than 1.4× control, unless therapeutically warranted.

Exclusion criteria included pregnancy; severe pulmonary, cardiac, or other systemic disease associated with an unacceptable anesthetic or operative risk; presence of an acute infection requiring active treatment; history of an autoimmune disorder; or prior history of other malignancies, excluding basal cell carcinoma and benign tumors. Patients were required to use a medically accepted form of birth control during the study.

There were 14 patients enrolled in the study (4 women and 10 men), with an age range from 28 to 61 years (Table 1). Patients with verified histological diagnoses of recurrent AA (three patients) or recurrent GBM (nine patients) were eligible and enrolled in this study after surgery. Newly diagnosed patients with GBM (one patient) and AA (one patient) were also enrolled.

Autologous Tumor Culture. After surgical resection, tumor samples were processed for culture by mincing them with scissors and passing them through metal meshes of decreasing pore size. The cell suspension was then plated onto tissue culture flasks and grown in DMEM/F10 (Irvine Scientific, Santa Ana, CA) plus 10% FCS (Irvine Scientific) and 1% penicillin/streptomycin (Invitrogen, Carlsbad, CA).

HLA Typing and Tumor Antigen PCR. Briefly, GBM cells were stained with biotin-conjugated HLA-A2- or HLA-A1-specific monoclonal antibody (US Biological, Swampscott, MA) or biotin-conjugated isotype control antibody. After streptavidin-PerCP (BD PharMingen, San Diego, CA) staining for 30 min, the Biocytin (Invitrogen, Carlsbad, CA) or biotin-conjugated isotype control antibody. After biotin-conjugated HLA-A2- or HLA-A1-specific monoclonal antibody (US Biological, Swampscott, MA) plus 10% FCS (Irvine Scientific) and 1% penicillin/streptomycin (Invitrogen, Carlsbad, CA).

Tumor samples from surgery were processed for culture by mincing them with scissors and passing them through metal meshes of decreasing pore size. The cell suspension was then plated onto tissue culture flasks and grown in DMEM/F10 (Irvine Scientific, Santa Ana, CA) plus 10% FCS (Irvine Scientific) and 1% penicillin/streptomycin (Invitrogen, Carlsbad, CA).

Table 1 Patient characteristics, treatment, and general clinical outcome

<table>
<thead>
<tr>
<th>Patient no.</th>
<th>Gender</th>
<th>Age (yrs)</th>
<th>Tumor pathology</th>
<th>Pre-vaccupKPS</th>
<th>Image complete resection</th>
<th>Pre-vacc Rx</th>
<th>Survival (weeks)</th>
<th>Adverse events</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>F</td>
<td>37</td>
<td>GBM</td>
<td>100</td>
<td>Yes</td>
<td>IC BCNU, BCNU</td>
<td>A. 238</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>M</td>
<td>46</td>
<td>GBM</td>
<td>100</td>
<td>No</td>
<td>Yes</td>
<td>79</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>M</td>
<td>28</td>
<td>AA</td>
<td>100</td>
<td>Yes</td>
<td>IC BCNU</td>
<td>32</td>
<td>Headache, fatigue</td>
</tr>
<tr>
<td>4</td>
<td>M</td>
<td>38</td>
<td>GBM</td>
<td>90</td>
<td>Yes</td>
<td>IC BCNU</td>
<td>238b</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>F</td>
<td>55</td>
<td>GBM</td>
<td>80</td>
<td>Yes</td>
<td>IC BCNU, SRS</td>
<td>183</td>
<td>Erythema</td>
</tr>
<tr>
<td>6</td>
<td>F</td>
<td>32</td>
<td>GBM</td>
<td>100</td>
<td>Yes</td>
<td>IC BCNU, BCNU</td>
<td>204b</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>M</td>
<td>34</td>
<td>AA</td>
<td>100</td>
<td>Yes</td>
<td>Antineoplaston, PCV</td>
<td>66</td>
<td>Headache</td>
</tr>
<tr>
<td>8</td>
<td>M</td>
<td>56</td>
<td>GBM</td>
<td>60</td>
<td>No</td>
<td>PCV, BCNU, SRS, IA Carbo, IC CCNU</td>
<td>138</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>M</td>
<td>44</td>
<td>GBM</td>
<td>90</td>
<td>No</td>
<td>BCNU</td>
<td>244b</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>M</td>
<td>42</td>
<td>AA</td>
<td>100</td>
<td>Yes</td>
<td>IC BCNU</td>
<td>29</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>F</td>
<td>47</td>
<td>GBM</td>
<td>100</td>
<td>Yes</td>
<td>IC BCNU</td>
<td>29</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>M</td>
<td>49</td>
<td>GBM</td>
<td>90</td>
<td>No</td>
<td>Tamoxifen, VP-16</td>
<td>90</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>M</td>
<td>61</td>
<td>AA</td>
<td>100</td>
<td>Yes</td>
<td>N</td>
<td>78</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>M</td>
<td>57</td>
<td>GBM-N</td>
<td>90</td>
<td>Yes</td>
<td>N</td>
<td>82</td>
<td></td>
</tr>
</tbody>
</table>

*Pre-vacc, prevaccination; KPS, Karnofsky performance score; Rx, treatment; GBM, glioblastoma multiforme; IC, intracranial; BCNU, 1,3-bis(2-chloroethyl)-1-nitrosourea; AA, anaplastic astrocytoma; SRS, stereotactic radiosurgery; PCV, procarbazine, IA, intra-arterial; Carbo, carboplatinum; CCNU, vincristine; -N, newly diagnosed.

b Patient still alive.
plates with a Harvester 96 cell harvester (Tomtec). Tritium \( ^3 \)H counts were determined with a Microbeta 1450 Trilux liquid scintillation counter (Wallac). Patients received 10^2-10^4 tumor-specific, tumor lysate-pulsed DCs s.c. in 0.5 ml of PBS in the deltoid region. Three vaccinations at 2-week intervals were administered to each patient.

**Immunohistochemistry.** Serial 10-μm paraffin sections of surgical intracranial tumor specimen were stained with mouse anti-human monoclonal antibodies against CD8 (C8/144B clone M7103 at 1:25 dilution), CD45RO (OPD4 clone M0834 at 1:50 dilution), CD20 (L26 clone M0755 at 1:200 dilution), and CD56 (T199 clone M0852 at 1:10 dilution; DAKO Corp., Carpenteria, CA). Primary antibodies were detected using the biotin-peroxidase system (DAKO Corp.).

**Cytotoxic T-Cell Assay.** A single patient grew sufficient autologous tumor cells to assess cytotoxicity using the FAM assay (15). Briefly, archived PBMCs were stimulated by autologous cultured tumor cells (irradiated with 11,000 rads) for 6 days in RPMI and recombinant human IL-2 (20 units/ml). Tumor cells were labeled as targets in \( ^{3} \)Hthymidine (5 μCi/ml) for 48 h in 5% CO₂. After incubation, target cells in maximum release wells were lysed with 5% SDS in H₂O and incubated in DNase 1 (Roche, Indianapolis, IN) at a final concentration of 20 units/ml for 10 min. Cells were harvested from plates with a Harvester 96 cell harvester (Tomtec). Tritium \( ^3 \)H counts were determined using a Microbeta 1450 liquid scintillation counter (Wallac).

**In Vitro Sensitization, RNA Isolation, and cDNA Synthesis.** Cryopreserved PBMCs from patients 1 week before therapy and 2 weeks after their third vaccination were thawed in complete medium. Cells were plated at 3 \( \times 10^5 \) PBMCs and 3 \( \times 10^5 \) DCs in 2 ml of medium with 10 μg/ml tumor lysate. IL-2 (300 IU/ml) was added on day 2, and the cells were harvested between days 10 and 13 after initiation of the culture. The harvested cells were then stimulated with tumor cells or autologous PBMCs pulsed with 10 μg/ml tumor lysate for 4 h at 37°C. The cells were collected to extract RNA with RNeasy minikits (Qiagen, Santa Clarita, CA). The RNA was eluted with water and stored at −70°C. For cDNA synthesis, about 1 μg of total RNA was transcribed with cDNA transcription reagents (Perkin-Elmer Corp., Foster City, CA) with the use of oligo(dT). cDNA was stored at −30°C until quantitative real-time PCR was performed.

**Quantitative Real-Time PCR.** Gene expression was measured with the use of the iCycler System (Bio-Rad) as described previously (16). Primers and TaqMan probes (Qiagen) were designed to span exon-intron junctions to prevent amplification of genomic DNA and also to produce amplicons of fewer than 150 bp to enhance the efficiency of PCR amplification. Probes were labeled at the 5′ end with the reporter dye molecule 6-carboxy-fluorescein (FAM; emission max = 518 nm) and at the 3′ end with the quencher dye molecule 6-carboxytetramethyl-rhodamine (TAMRA; emission max = 582 nm). On amplification, the probes annealed to the template were cleaved by the 5′-nuclease activity of the Taq polymerase reaction. This process separates the fluorescent label from the quencher and allows release of 1 unit of fluorescence for each unit of amplification. The amount of fluorescence required with each copy number was performed for both IFN-γ and CD8a. Normalization of sample data was done by dividing the number of copies of IFN transcripts by the number of copies of 18S rRNA transcripts, representing the relevant cell population. The results of IFN-γ fold increase postvaccination compared with prevaccination were presented.

Data were adjusted for CD8 mRNA copies on the basic immunological assumption that stimulation with a HLA class I-restricted epitope defines CD8+ T cells as the only relevant population. Because the frequency of CD8+ T cells varies over time in each patient, we believe that it is suboptimal to present data corrected by expression of housekeeping genes, such as glyceraldehyde-3-phosphate dehydrogenase or β-actin, expressed by any cell, even though this correction has been done in other quantitative real-time PCR applications. We calculated the ratio of IFN-γ mRNA (corrected for CD8 mRNA) obtained from PBMCs stimulated with autologous tumor lysate to that obtained from PBMCs stimulated without tumor lysate. The cutoff value for tumor-specific IFN-γ was derived by analyzing the IFN-γ:CD8 ratios in PBMCs obtained from all patients postvaccination versus prevaccination. A cutoff value of 1.5 has been published standard for evidence of vaccine-related tumor-specific cytotoxic response (16).

**Epitope-Specific T-Cell Staining with HLA-A*0201 Tetramers.** Peptide-loaded HLA tetramer (tHLA) complexes were synthesized and provided by Beckman Coulter as described previously (17). Recombinant HLA-A*0201 or HLA-A201 heavy chain containing a biotinylation site and recombinant β2-microglobulin were synthesized and used for refolding of soluble HLA (sHLA) molecules in the presence of a HLA-A*0201 binding peptide. sHLA molecules were prepared for the following epitopes: HLA-A1-restricted MAGE-1 (amino acids 161–169) antigen peptide (EAAPGTGHSY); HLA-A2-restricted HER-2 (amino acids 369–377) peptide (KIFGSLALI); and gp100 (amino acids 209–217) peptide (ITDQVPFSV). All peptides were commercially synthesized and purified by gel filtration (Macromolecular Re- source, Fort Collins, CO). The refolding reaction was dialedyzed and concentrated for purification of correctly refolded sHLA on gel filtration. Monomeric sHLA was biotinylated with BirA (Avidine, Denver, CO) at the heavy chain and separated from free biotin by gel filtration. Biotinylated sHLA was tetramerized by adding avidin-PE (Pierce, Rockford, IL) at a 4:1 molar ratio. The final concentration of tetramer was adjusted to 1 μg/ml. As examined by gel filtration, all HILAs were without detectable free avidin-PE. After overnight depletion of monocytes, nonadherent PBMCs were resuspended at 10⁶ cells/50 μl in ice-cold fluorescence-activated cell-sorting buffer (phosphate buffer plus 5% inactivated FCS; Biofluids), and cells from day 10 CTL cultures were washed and resuspended at 2 \( \times 10^5 \) cells/50 μl in cold fluorescence-activated cell-sorting buffer. Cells were incubated on ice with 1 μg of sHLA for 15 min, and incubation was then continued for 30 min with 10 μl of anti-CD8 monoclonal antibody (Becton Dickinson, San Jose, CA). Cells were washed twice in 2 ml of cold fluorescence-activated cell-sorting buffer before fluorescence-activated cell-sorting analysis (Becton Dickinson). Two hundred thousand events were acquired. HILA staining specificity was previously established by extensive analysis of T-cell clones specific for each of the described epitopes and by comparative analysis of short-term CTL cultures also specific for the above-mentioned epitopes (18).

**Statistical Analysis.** Data were analyzed with a SAS statistical software package. Means are reported with SD. Continuous variables were compared using Student’s \( t \) test, and categorical variables were compared using \( \chi^2 \) or Fisher’s exact test. Any \( P \) values less than 0.05 were considered statistically significant. The estimated probability of survival was demonstrated using the Kaplan-Meier method. The Mantel Cox log-rank test was used to compare curves between study and control groups.

**RESULTS**

Isolation and Characterization of DCs. In this study, each patient’s tumor was resected, and the surgical tissue was lysed and used as an antigen source. Mononuclear cells were isolated by Ficoll gradient centrifugation and differentiated into DCs in the presence of IL-4 and granulocyte macrophage colony-stimulating factor. DCs from each study patient were shown to develop high levels of MHC class II and costimulatory molecule B7-2 (CD86) and showed the absence of markers for mature monocytes (CD14) and macrophages...
CD11b). DCs were CD54+,
CD40+,
and phenotypically immature (CD83−). Allogeneic proliferation assays confirmed that the DCs isolated were functional (Fig. 1). Furthermore, sufficient numbers of functional DCs were isolated in all patients in this clinical trial (at least 1 × 10^7 cells for each of three vaccinations). DCs were differentiated, cocultured with autologous tumor lysate, washed, and administered to patients thrice over the course of 6 weeks.

**Safety of Autologous DC Administration.** There were no grade III or IV National Cancer Institute Common Toxicity Criteria adverse affects associated with vaccination in this trial. There were no serious adverse events other than death from tumor progression. Three patients complained of transient headaches that were relieved by analgesics on 1, 3, and 5 days after one of the vaccinations (Table 1). Two patients complained of fatigue during the course of the treatment (Table 1). One patient developed erythema at the site of vaccination. Two patients developed generalized seizures 5 and 7 days after vaccination, which resolved with antiepileptic medication. There was no clinical or radiological evidence of autoimmune response in any patient. Autopsies performed on two patients did not show evidence of an autoimmune response. There were some CD45RO+ memory T cells observed in areas of tumor in the brain of one of these patients. CD8+ cytotoxic cells were infrequently observed in the tumors of both patients.

**Development of Systemic Cytotoxicity.** One goal of this clinical trial was to determine whether ex vivo differentiation of DCs and exposure to tumor lysate antigen could induce an immune response after vaccination of malignant glioma patients. Because of previous treatment of patients with radiation, the tumor specimen from only a single patient grew sufficient glioma cells in culture to test cytotoxicity through a conventional CTL assay. Cytotoxicity of PBMCs directed toward autologous tumor cells was assessed in patient 2. This patient demonstrated significant tumor cytotoxicity as early as 1 week after his second vaccination, and this cytotoxicity was sustained after his third vaccination. Ten additional patients underwent measurement of CTL responses through a reverse transcription-PCR-based method to measure IFN-γ mRNA expression. The method controlled for CD8+ mRNA in PBMC samples taken 1 month after the last vaccination as compared with prevaccination samples. Six of 10 patients elicited significant IFN-γ mRNA accumulation in response to autologous tumor lysate after vaccination as determined by at least a 1.5-fold increase in IFN-γ mRNA postvaccination (Table 2).

**DC Vaccination Induces the Expansion of Tumor Antigen-Specific Cytotoxic T-Cell Clones.** The distribution of HLA-A2 and HLA-A1 and expression of TAAs HER-2, MAGE-1, and gp100 are shown in Table 3. Based on the prevalence of certain TAAs in primary glioma cells, we investigated whether PBMCs from vaccinated pa-

---

**Table 2. Identification of vaccine-specific CD8+ T cells in PBMCs of patients by IHLA staining and IFN-γ expression by real-time PCR**

PBMCs isolated from glioma patients before and after vaccination with tumor lysate-pulsed dendritic cells were assessed for tumor-specific cytotoxicity by means of quantitative PCR for IFN-γ message after in vitro exposure to autologous tumor lysate as well as for the presence of antigen-specific CD8+ CTL clones using flow cytometry for HLA-restricted tetramer staining. Tumor-specific cytotoxicity was determined to be positive if IFN-γ message in postvaccination PBMCs was at least 1.5× greater than that in prevaccination PBMCs (bold values; see "Materials and Methods." Numbers in the CTL columns represent the percentage of CD8+ cells that stained positive for antigen-specific tetramer binding.

<table>
<thead>
<tr>
<th>Patient no.</th>
<th>IFN-γ fold increase</th>
<th>HER-2-specific CTLs</th>
<th>gp100-specific CTLs</th>
<th>MAGE-1-specific CTLs</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Post vs. Pre</td>
<td>Pre</td>
<td>Post</td>
<td>Pre</td>
</tr>
<tr>
<td>3</td>
<td>0.96</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>4</td>
<td>ND</td>
<td>0.3</td>
<td>0.91</td>
<td>0.17</td>
</tr>
<tr>
<td>5</td>
<td>5.32</td>
<td>ND</td>
<td>ND</td>
<td>0.12</td>
</tr>
<tr>
<td>6</td>
<td>2.73</td>
<td>0.37</td>
<td>2.2</td>
<td>0.09</td>
</tr>
<tr>
<td>7</td>
<td>1.6</td>
<td>0.5</td>
<td>1.82</td>
<td>0.09</td>
</tr>
<tr>
<td>8</td>
<td>0.61</td>
<td>0.02</td>
<td>0</td>
<td>0.02</td>
</tr>
<tr>
<td>9</td>
<td>7.14</td>
<td>ND</td>
<td>ND</td>
<td>0.02</td>
</tr>
<tr>
<td>10</td>
<td>1.54</td>
<td>ND</td>
<td>ND</td>
<td>0.01</td>
</tr>
<tr>
<td>12</td>
<td>1.55</td>
<td>ND</td>
<td>ND</td>
<td>0.16</td>
</tr>
<tr>
<td>13</td>
<td>0.57</td>
<td>0.99</td>
<td>0.11</td>
<td>0.55</td>
</tr>
<tr>
<td>14</td>
<td>1.02</td>
<td>0.63</td>
<td>0.29</td>
<td>0.85</td>
</tr>
</tbody>
</table>

*PBMC, peripheral blood mononuclear cell; IHLA, peptide loaded HLA tetramer; Post, postvaccination; Pre, prevaccination; ND, not done (due to insufficient cells to perform real-time PCR or HLA-A2/A1 mismatch for specific tetramer analysis).
Patients contained CTL clones specific for these antigens including gp100, HER-2, and MAGE-1. Using HLA-restricted tetramer staining, we identified a significant increase in the number of CD8+ antigen-specific T-cell clones after DC vaccination in four of nine informative patients (Table 2). All three positive, informative patients also demonstrated cytotoxicity based on IFN-γ mRNA expression of PBMCs in response to tumor lysate. Fig. 2 shows the tetramer analyses of the four positive patients.

**Intratumoral T-Cell Infiltration.** We then investigated whether these immune responses could access intracranial tumor. We analyzed tumor tissue for immune cell infiltration from patients who underwent surgical resection after radiologically identified disease progression. We identified CD45RO+ memory T cells and CD8+ cytotoxic T cells in surgical specimens isolated from three of six patients vaccinated with tumor lysate-primed DCs. This T-cell infiltration was not present in tumor tissue resected from the same patients before vaccination therapy. Patient 2 developed tumor recurrence as shown by magnetic resonance imaging with a gadolinium-enhancing mass 3 months after his last vaccination. He underwent re-resection of the mass. There was a moderate number of CD45RO+ memory T cells present in the surgical specimen, whereas there were few cells observed in the surgical specimen from his operation before vaccination (Fig. 3). There was also significant CD8+ cell infiltration in the postvaccination surgical specimen, which was infrequently detected in his surgical specimen before vaccination (Fig. 3).

**DC Vaccination Is Associated with Prolonged Survival.** A further objective of this study was to determine the clinical response to DC vaccination. Therefore, we compared survival in our patient populations with age, gender, and disease-matched controls, who had not received DC therapy. Study patients with recurrent GBM were included in a survival analysis. Therefore, the four patients with AA, a patient with newly diagnosed GBM, and a patient with recurrent...
GBM who received only two vaccinations because of noncompliance were excluded from the survival analysis. There were 8 patients in the study group 26 in the control group with recurrent GBM who underwent craniotomies at our institution. Control patients underwent repeat craniotomy by the same surgeons as the study group and had completed external beam radiation therapy of 60 Gy. They met all inclusion criteria for the DC immunotherapy trial, including a Karnofsky score of ≥60, but were treated before the trial opening (within 2 years) or chose not to participate. There were no statistically significant differences between the study and control groups for age (44.0 ± 9.1 versus 53.0 ± 13.8 years; P = 0.09) or percentage of patients with image complete resections (50% versus 58%; P = 1.0). The median survival for the study and control groups was 133 and 30 weeks, respectively. The Mantel Cox log-rank test revealed that the survival curves for the two groups were significantly different (P = 0.0013; Fig. 4.).

DISCUSSION

Previous immunotherapeutic treatments for brain tumors used passive, adoptive, and nonspecific strategies that yielded limited benefits (19). These treatments included the intrathecal or intratumoral administration of autologous lymphocytes, IL-2, lymphokine-activated killer cells, or IFNs (20–23). The absence of a significant antitumor effect in these prior studies may have been due to the nonspecific immune response that these approaches generate. Active immunotherapy requires the presentation of tumor antigens by antigen-presenting cells with the goal of inducing an antigen-specific T-cell response.

To investigate the potential of this therapy in a clinical setting, we used DC-based vaccination protocols in two Phase I clinical trials. Through these trials, we demonstrated the safety and bioactivity of this immunotherapy approach in patients with malignant brain tumors. The first trial involved nine patients with newly diagnosed glioma (seven patients with GBM and two patients with AA), who were treated with a series of three intradermal vaccinations of DCs pulsed ex vivo with autologous tumor cell surface-derived peptides isolated by means of acid elution (12). The second clinical trial involved 14 patients, 12 of whom had recurrent disease (9 patients with GBM and 3 patients with AA), whereas 2 patients were newly diagnosed (1 patient each with GBM and AA). These patients received DC vaccines that had been pulsed ex vivo with whole tumor lysate, which we hypothesized could serve as an optimal source of as yet unidentified immunogenic tumor antigens.

In this Phase I trial, patient tumors were resected, and tumor lysate from surgically removed tumor was used as an antigen source. We reasoned that this approach could have the following advantages: (a) it could provide multiple antigens for recognition by specific T cells. Gliomas are heterogeneous tumors among patients as well as within an individual patient, and there are no known defined TAAs expressed by all glioma cells. (b) Tumor lysate does not require growing autologous cultured tumor cells, which is difficult with irradiated tumor tissue. (c) Cultured GBM cells have the risk of expressing artificial antigens as a result of culturing. (d) Targeting multiple antigens could be advantageous and obviate immune selection of single antigen-loss tumor variants.

The isolation of tumor lysate provided a patient-specific and tumor-associated mixture of potential T helper and CTL epitopes whose characterization or purification was not required. Mononuclear cells were isolated through leukapheresis, yielding approximately 2.5 × 10^7 DCs after ex vivo differentiation in the presence of IL-4 and granulocyte macrophage colony-stimulating factor. This yield of DCs was 25-fold greater than that used in our first Phase I trial for patients with newly diagnosed tumors (12). Allogeneic proliferation assays confirmed that the DCs isolated were functional, and sufficient numbers were isolated in all patients to administer three intradermal vaccinations.

The vaccinations were well tolerated with no significant toxicities, similar to reports from other DC immunotherapy trials (8–11). Mild toxicities included three episodes of transient headache after vaccination. Two patients complained of chronic fatigue. To date, no clinical or radiological features of autoimmune disease have been detected in our patients, nor have other DC immunotherapy trials reported any significant autoimmune disease (8–11). Autopsies of two patients confirmed the presence of tumor with some infiltration by CD45RO+ memory T cells. There was a paucity, however, of CD8+ cytotoxic T cells in both autopsies. No evidence of autoimmune response was observed in the autopsied brains. Continued evaluation will be necessary to determine whether autoimmunity may develop as a late complication of DC vaccination.

With our previously published tumor peptide-pulsed DC therapy, cytotoxic immunity was detected in four of nine patients (12). Here, vaccination with tumor lysate–primed DCs elicited significant cytotoxic responses against tumor in 6 of 10 patients, as determined by quantitative PCR analysis of IFN-γ message in restimulated PBMCs (Table 2). These results demonstrate that the use of unselected tumor-derived antigenic preparations can effectively induce antitumor cytotoxicity. However, the accumulation of IFN-γ message does not necessarily mean that it will be translated into functional protein. To further determine whether T-cell clones to specific antigen were being generated from DC vaccination, we sought to analyze the presence of CTL clones that recognized TAA epitopes through the use of tetramers. We previously demonstrated the presence of MHC class I–restricted CTLs, which recognized the TAA TRP–2, in a subset of glioma patients treated with DC vaccinations (13). We subsequently investigated the expression in glioma of TAAs related to breast carcinoma and melanoma, including HER-2, gp100, and MAGE-1. We demonstrated that of 43 primary GBMs analyzed, HER-2, gp100, and MAGE-1 mRNA was expressed in 81.4%, 46.5%, and 39.5% of respective samples (14). Of significance was our finding that among tumors derived from the 14 patients treated with lysate-pulsed DC vaccinations, HER-2, gp100, and MAGE-1 mRNA was expressed at 71.4%, 50%, and 50%, respectively. Twelve of 14 (85.7%) patients expressed at least one of these antigens, with 4 tumors expressing all three antigens (HER-2, MAGE-1, and gp100; Table 3). Nine patients

![Fig. 4. Kaplan-Meier survival curve of study group (n = 8; solid line) and control group (n = 26; dashed line) of patients with recurrent glioblastoma multiforme from time of second craniotomy (P = 0.003, log-rank test).](https://example.com/fig4.png)
expressed at least one of these antigens in an MHC class I-restricted manner. Of these patients, four demonstrated positive epitope-specific CTLs after vaccination. Each of these positive, informative patients also demonstrated strong posttreatment antitumor cytotoxicity, as determined by quantitative PCR measurement of IFN-γ message in restimulated PBMCs (Table 2). Despite the identification of these antigens on glioma cells and the presence of specific CTL clones within vaccinated patients’ PBMCs, however, the exact contribution of these antigens to the antitumor cytotoxic response remains unclear. It is possible that the therapeutic effects observed may result from the additional presentation of as yet uncharacterized immunogenic tumor antigens. The ability to use HER-2, MAGE-1, and gp100 as markers for assessing antigen-specific immune responses, however, as opposed to the use of nonspecific, tumor-derived, mixed antigen preparations in which individual immunogenic targets may be highly diluted, provides us with a powerful tool to monitor the efficacy of immunotherapeutic protocols.

We identified CD45RO+ memory T cells and CD8+ cytotoxic T cells in surgical specimens isolated from three of six patients vaccinated with tumor lysate-primed DCs. The intratumoral infiltration of CD45RO+ T cells is similar to the infiltration seen in delayed-type hypersensitivity sites and in regressing tumors in a DC immunotherapy trial for patients with melanoma (10). The intratumoral presence of these previously activated and/or memory T cells suggests that DC vaccination may elicit activated T cells with specific homing or expansion properties. The patients who underwent reoperation were, by definition, treatment failures. The presence of cytotoxic T cells in these tumors suggests that the presence of radiological recurrence does not indicate the absence of a cytotoxic immunological response, but rather a shift in the homeostasis of tumor growth overcoming T-cell killing.

Of significance was our finding that patients treated with DC vaccinations demonstrated markedly prolonged survival compared with historical controls (Fig. 4). These findings indicate the possible therapeutic relevance of the observed enhancement in tumor-specific cytotoxicity and confirm the viability of DC therapy for glioma. Patients with recurrent GBM treated with DC vaccinations appear to have prolonged survival compared with patients who undergo craniotomy and conventional treatment. Leukapheresis was used to isolate 25-fold more DCs for vaccination than we were able to generate for our trial of patients with newly diagnosed GBM and AA (12). This augmented number of DCs used for vaccination may increase the T-cell response and may account for the robust increase in survival of recurrent GBM patients in this trial compared with our Phase I DC trial for patients with newly diagnosed malignant glioma. The use of tumor lysate in this trial rather than acid-eluted MHC-associated peptide from cultured GBM cells also represented a divergence from the previously reported trial.

A Phase II study is under way to reassess the role that DC therapy may have in prolonging survival. Okada et al. (24) have used an alternative autologous DC strategy to treat recurrent GBM, and the results of this Phase I study are pending. Physician selection and patient bias cannot be completely ruled out in this study, although age, gender, and degree of resection were not significantly different in the study and control groups. Selection bias can only be eliminated by a randomized Phase III study. The successful induction of systemic tumor and antigen-specific cytotoxicity associated with intracranial cytotoxic T-cell infiltration establishes this immunotherapy strategy as a model to help to understand the mechanisms underlying adaptive immunity against glioma.

REFERENCES
Vaccination with Tumor Lysate-Pulsed Dendritic Cells Elicits Antigen-Specific, Cytotoxic T-Cells in Patients with Malignant Glioma

John S. Yu, Gentao Liu, Han Ying, et al.


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/64/14/4973

Cited articles
This article cites 24 articles, 7 of which you can access for free at:
http://cancerres.aacrjournals.org/content/64/14/4973.full.html#ref-list-1

Citing articles
This article has been cited by 42 HighWire-hosted articles. Access the articles at:
/content/64/14/4973.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.